Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing by Fallowfield, Lesley et al.
Endorevision 25 Jan 2018  
1 
 
Running title: enhancing decision-making re adjuvant chemotherapy in breast cancer 
 
Enhancing decision-making about adjuvant chemotherapy in early breast 
cancer following EndoPredict testing  
 
Lesley Fallowfield1, Lucy Matthews1, Shirley May1, Valerie Jenkins1, David 
Bloomfield2 
 
1Sussex Health Outcomes Research & Education in Cancer (SHORE-C) 
Brighton & Sussex Medical School 
University of Sussex 
Falmer 
Brighton BN1 9RX 
 
 
2 Sussex Cancer Centre 
Brighton & Sussex University Hospitals Trust 
Eastern Road 
Brighton BN2 5DA 
 
 
 
 
 
 
 
 
 
Corresponding author 
Professor Dame Lesley Fallowfield 
Sussex Health Outcomes Research & Education in Cancer (SHORE-C) 
Brighton & Sussex Medical School 
University of Sussex 
Falmer 
Brighton BN1 9RX 
 
Tel: +44 1273 873015 
Email: l.j.fallowfield@sussex.ac.uk 
 
Endorevision 25 Jan 2018  
2 
 
Objective: Chemotherapy side-effects can be substantial. There is increasing 
recognition that some oestrogen receptor positive (ER+ve), human epidermal growth 
factor receptor 2 negative (HER2–ve) patients with breast cancer derive no benefit 
from chemotherapy and experience only iatrogenic harm. Gene expression profiling 
tests help refine recurrence risk and likely chemotherapy benefit. EndoPredict® is 
one such test, which classifies risks of distant recurrence as low or high in patients 
treated with surgery and adjuvant endocrine therapy alone.  We compared treatment 
decisions pre and post test results, patients’ anxiety, decisional conflict and 
oncologists’ confidence about the decisions made.   
Methods: 14 oncologists in 7 UK hospitals saw 149 pts judged to have equivocal 
indications for chemotherapy. Provisional treatment decisions were recorded then 
reconsidered when EPClin results were available. Pre and post test results, patients 
completed State/Trait Anxiety Inventories (STAI) and the decisional conflict scale 
(DCS). Oncologists also recorded basic clinical details, their agreement with, and 
confidence about treatment decisions. 
Results: 67% patients initially prescribed endocrine alone with high risk result 
upgraded to endocrine+chemotherapy (E+C); 83% prescribed E+C and had low risk 
scores, downgraded to E. None of 46 patients initially favouring E alone, who were 
low risk changed decisions. Oncologists’ confidence about decisions was 
significantly increased following the results (p=0.002). Patients with downgraded 
treatment decisions had significantly lower anxiety scores (p=0.045); those upgraded 
had increased scores (p=0.001). Overall decisional conflict and uncertainty fell 
significantly post-test (p<0.022). 
Conclusions: EndoPredict scores increased oncologists’ and patients’ decision-
making confidence, generally improving the matching of risk with therapy decisions.  
 
Keywords: Gene expression profiling, EndoPredict®, decision-making, anxiety, 
breast cancer, communication, cancer, oncology, treatments, oncologists 
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Background 
Balancing the harms as well as the putative benefits of all breast cancer treatments 
is a vital component of decision-making. Side-effects of chemotherapy such as hair 
loss, fatigue, nausea and vomiting can be substantial and exert a deleterious impact 
on body image and quality of life1.  Coping with some of these side-effects may be 
more tolerable if patients feel that the risks of recurrence are significantly reduced. 
Conversely over-treatment with drugs that make little or no difference to a patient’s 
recurrence risk needs to be avoided. Establishing the risk of early and late stage 
recurrence in early breast cancer can be capricious. Historically features including 
tumour size, histological grade, type, nodal involvement and lympho-vascular 
invasion were seen as useful prognostic indicators; these characteristics, together 
with biomarkers such as oestrogen receptor/progesterone receptor (ER/PR) and 
human epidermal growth factor receptor (HER) status, help to determine which 
patients have a greater risk and therefore potentially better outcome with and without 
adjuvant therapy2. As further data emerge regarding the longer term risks of distant 
recurrence, certain tests may also help to determine how long patients should be 
encouraged to continue with endocrine therapy. 
More recent biomarker research has focused on the development of prognostic and 
ultimately predictive tests to ensure that systemic endocrine and/or chemotherapy is 
only given to those patients with tumour characteristics that might make response 
more likely and worthwhile. The gene expression profiling tests such as Breast 
Cancer Index, Mammaprint® and OncotypeDX® can assist in the estimation of risk 
of recurrence3. EndoPredict® is another multigene expression profiling test for 
predicting the likelihood of distant recurrence in patients with ER-positive, HER2-
negative breast cancer treated with adjuvant endocrine therapy only4. The test 
reports an EP score, using just the molecular parameter and an EPClin score that 
includes relevant clinical parameters. Two large randomized phase III trials [Austrian 
Breast and Colorectal Cancer Study Group (ABCSG)-6 and ABCSG-8] have shown 
that the test can identify subgroups that have differences in their 10-year distant 
recurrence rates5. Additionally, the EP/EPClin classifier adds substantially prognostic 
information to clinico-pathological parameters, including Ki67 staining4.  A 
retrospective review on tissue blocks from the ATAC study also showed that 
integrating tumour size and nodal status with the molecular data, increased 
prognostic information6. The EPClin score can help clinicians by delineating the risks 
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of distant recurrence as low or high for ER+, HER2-negative patients treated with 
adjuvant endocrine therapy alone. 
Because of the many advances made in diagnostic testing, surgical and radiotherapy 
techniques and the many new systemic therapies available, decision making about 
treatment options in breast cancer has become more complex. Patients may need to 
make multiple decisions within a short space of time and all conversations take place 
against a backdrop of fear and uncertainty. Health literacy and numeracy are often 
quite poor and lay populations generally subscribe to the notion that in the context of 
life-threat, more treatment must be better than less. Given the fears about the 
potential for death from metastatic breast cancer, it is not surprising that both 
patients and clinicians will consider every additional therapeutic option with a 
resultant potential overtreatment with systemic chemotherapy7.  
For some patients with early stage breast cancer, the clinic-pathologic features of the 
tumour such as size, nodal, ER and HER2 status are sufficiently clear for oncologists 
to either recommend or omit adjuvant chemotherapy. Some have found visual aids 
such as PREDICT or Adjuvant!, which show survival benefits with or without 
adjuvant hormone and chemotherapy helpful, although understanding of the graphs 
from these is dependent on basic numeracy. There is research demonstrating that 
genomic test scores may permit clinicians to discuss the pros and cons of 
chemotherapy treatment recommendations with more confidence and may help 
patients to make more informed choices8. Provision of the risk of recurrence from a 
gene expression profiling test such as EndoPredict may help in those situations 
where the likely benefit of adjuvant chemotherapy is equivocal. Only one small 
Austrian study previously has shown that Endopredict results can alter the decision 
to recommend chemotherapy made using traditional clinical parameters9. 
In this study we compared pre and post EndoPredict test results: - adjuvant 
treatment decisions, the patients’ anxiety, their decisional conflict and oncologists’ 
confidence about decisions made.  
 
Methods 
A non-randomised prospective cohort study measuring decision-making for adjuvant 
chemotherapy before and after EndoPredict testing. Study objectives included:- 
1) comparison of treatment decisions before and after EndoPredict test results 
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2) measurement of the cost-utility of EndoPredict testing (to be reported 
separately) 
The primary psychosocial outcomes were the impact that knowledge about the risk 
of recurrence had on anxiety and decisional conflict of patients, and oncologists’ 
confidence about the treatment decisions made pre and post-test.   
The primary quantitative outcome was the change in decision made by the patient 
and clinician about adjuvant chemotherapy as a result of the additional information in 
the EndoPredict test.  
Participants were recruited to the study between July 2015 and October 2016 from 7 
UK hospitals by 14 breast cancer specialist oncologists.  Written informed consent 
was obtained prior to all data collection. Ethical approval (South Central – Oxford C 
Research Ethics Committee ref: 15/SC/0090), and NHS R&D permissions were 
obtained for each centre and adopted by the NIHR Portfolio (ref: 19287). Women 
with early stage, ER+ HER2-negative breast cancer who were judged by their 
multidisciplinary teams (MDTs) to have equivocal indications for chemotherapy and 
able to read English, were eligible to join the study.  
 
Recruitment  
Post-operatively prospective patients were discussed by their treating multi-
disciplinary team (MDT). Those identified as potentially eligible were either given a 
Patient Information Sheet (PIS) by a member of the breast team at the post-surgical 
review, or sent a covering letter and PIS in the post prior to their first oncology 
consultation.  
The treating oncologist discussed histological results including size, grade, nodal 
status, ER and HER-2 status with patients as part of their normal care, and used 
standard clinical-pathological criteria to estimate the likely benefit from adjuvant 
chemotherapy. Those patients judged by the MDT to be in an intermediate risk group 
using standard clinico-pathologic criteria were asked by the oncologists, after a 
careful consideration of the facts, to make a provisional treatment decision – either to 
have or to omit adjuvant chemotherapy. These shared decisions were recorded 
together with the chemotherapy regimen if appropriate in the notes and on the CRF 
(see appendices 1a & b). 
Eligible patients who had read the PIS had a discussion about the EndoPredict test 
with their oncologist. If they consented to the study, their tissue was sent for analysis 
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and an appointment made for a further consultation. A provisional referral for 
chemotherapy was made to minimise any delay in subsequent treatment whilst 
awaiting the test result.  
Patients and oncologists met for a second consultation within 2 weeks when the 
EndoPredict test results were available and the decision about adjuvant 
chemotherapy reviewed. Patients completed the Decisional Conflict Scale (DCS)10 
and the Speilberger (STAI) trait and/state anxiety questionnaire11 following their 
initial decision-making and the DCS and STAI (state) after the risk of recurrence 
scores had been discussed. Oncologists recorded their confidence in the decision 
made at both time points. 
 
Assessments  
The DCS assesses an individual’s uncertainty when choosing between options, and 
factors contributing to that including feeling uninformed and unsupported. Decisional 
conflict can also be affected by issues such as pressure from others, lack of clarity 
about options, pre-existing or unrealistic expectations. All of these are areas that 
might be experienced by women considering adjuvant therapy. The DCS is 
comprised of 16-items with a 5-point Likert categorical response scale: ‘strongly 
agree’, ‘agree’, ‘neither agree nor disagree’, ‘disagree’ and ‘strongly disagree’. It 
provides a total score from all 16 items and 5 possible sub-scores (informed, values 
clarity, support, uncertainty and effective decision). Total scores range from 1-100 
with higher scores denoting more decisional conflict. The instrument has good 
psychometric properties.  
The STAI consists of 2 questionnaires with 20 items rated on simple 4 point scales. It 
is one of the most widely used well-known, validated research clinical tools for 
evaluating anxiety proneness (Trait) and the current state of anxiety or anxiety 
change (State). It is self-administered and takes approximately 10 minutes to 
complete and it has been used successfully in many breast cancer studies. High 
STAI scores signify greater anxiety. The Trait anxiety is measured only once and the 
State at each time point.  
Oncologists completed forms about provisional treatment decisions and confidence 
in their decisions based on the usual clinic-pathologic features and again following 
their consultations with patients when EPClin scores were available (Appendices 1a 
&b). 
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Statistical Methods 
Standard scoring rules were followed for the DCS and STAI. Means and change 
scores were calculated and paired t-tests or Chi2 statistics used as appropriate to 
determine significance of these between initial and post EndoPredict test decisions. 
Doctors' confidence pre and post-test was compared using Chi2 statistics. 
Pre and post-test means and score changes for the STAI and DCS scales were 
compared using T-tests. 
All scores were based on raw data, without imputation. DCS responses were 
originally based on a 1-5 scale where 1=strongly agree and 5=strongly disagree, and 
converted to percentages.  DCS sub-scales were calculated where there were 2 or 
more responses.  Total DCS scores were calculated where there were 2 or more 
responses for all sub-scales.  STAI scores were calculated where there were fewer 
than 2/20 missing responses. 
Results 
One hundred and fifty-one patients were enrolled into the study of whom 149 were 
eligible and completed the study. (2 patients did not have EndoPredict test data 
available for evaluation for technical reasons). Table 1 shows patient characteristics. 
Insert Table 1 
The median Nottingham Prognostic Index was 3.76. Of 149 tested tumours, 99 had 
no evidence of nodal metastases, 29 had macro-metastases and a further 21 
micrometastases alone. All patients were ER positive and Her-2 negative as entry 
criteria for the trial. 
EndoPredict test results  
The initial shared decision for 88 patients (59.1%) was endocrine treatment alone 
and for 61(40.9%) endocrine therapy plus chemotherapy. Table 2 shows that of 
those favouring endocrine treatment alone initially 42 had high risk EPClin scores 
and 66.7% of these upgraded to endocrine and chemotherapy. None of the 46 
patients who initially favoured endocrine alone and who had low risk EPClin scores 
had a change in decision. The 32 patients who had initially opted for endocrine and 
chemotherapy with high risk EPClin scores generally kept to that decision although 3 
(9.4%) downgraded to endocrine alone. The patients with low risk scores mainly 
downgraded to endocrine alone although 5 (17.2) kept to their original decision. 
 
Insert Table 2 
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In response to the statement “as the treating clinician I am confident with the 
decision made today” oncologists were significantly more likely to strongly agree 
post-test (50%) compared to pre-test (8%) P=0.002. 
Patients’ Anxiety 
STAI state anxiety scores were stable in patients with unchanged decisions for 
endocrine alone or endocrine plus chemotherapy. Those patients whose therapy 
was downgraded (27/61) had significantly lower state anxiety scores (P=0.045) 
whereas those whose treatment was upgraded had increased scores (P=0.001). 
There was no significant difference in state scores pre-post test in those who had 
high or low trait anxiety. 
Decisional Conflict 
Table 3 shows the total scores and the 5 subscale scores on the DCS. Post-test 
patients were less uncertain, more informed and felt more effective. Decisional 
conflict was reduced significantly (P=0.022) but this was influenced by those patients 
whose treatment remained unchanged (94/149).  
Insert Table 3 
Table 4 shows that patients with unchanged decisions had significantly lower 
uncertainty scores (mean change 4.78, P=0.001). In those for whom treatment was 
downgraded, it fell slightly ((27/149) mean change 1.87) and uncertainty increased 
(mean change -1.07) where treatment was upgraded (28/149).  
Insert Table 4 
Discussion 
The appropriate use of gene-expression profiling tests has the potential for 
maximising benefit and reducing iatrogenic harm. This study showed that EPClin test 
results increased oncologists’ and patients’ decision-making confidence. The 
matching of risk scores with therapy decisions was mainly improved although some 
post-test decisions need further examination. Our results are similar to other 
prospective decision impact studies using 21 gene assays where adjuvant treatment 
decisions changed in at least 25% of patients and decisional conflict decreased too9, 
12-13. 
All decision-making requires the balancing of likely absolute benefits in terms of 
preventing recurrence versus the treatment related side effects. Health literacy and 
numeracy skills in the general population are often poor thus explaining risk and 
uncertainty can be confusing especially when set against a backdrop of fear and 
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anxiety. We do not know from this study why some patients with a high risk score did 
not wish to have chemotherapy or why those with low scores chose to have 
chemotherapy nevertheless. One can hypothesise that fear or anecdotal experience 
of others known to the patients might have had an influence. Another possible 
explanation is that the oncologists themselves had other idiosyncratic reasons for 
endorsing and altering suggestions about treatments. Healthcare professionals’ own 
communication about risks harms and benefits are subject to unconscious bias and 
misunderstanding. Interesting research has identified that all individuals (this would 
include health care professionals as well as patients) have different tolerances to 
uncertainty. Those with a high intolerance to uncertainty might have inadvertently 
communicated scores in a somewhat nuanced, negative manner especially if the 
score were borderline low or high risk.  
Clinical implications 
There is recognition that not all women with early breast cancer need or benefit from 
adjuvant chemotherapy. Many lay populations feel that in the context of life 
threatening disease more treatment must be better. Gene expression profiling tests 
provide a risk of recurrence score that should enable wiser decision-making. This 
study showed that in general the receipt of risk scores helped doctors feel more 
confident about decisions. Patients felt less decisional conflict and for those who had 
treatment decisions downgraded from chemotherapy to no chemotherapy, anxiety 
significantly decreased. 
Study limitations 
This was a small study and had a few surprising findings as not all decisions 
appeared rational. Further work needs to be done exploring the communication of 
risks of recurrence scores with anxious patients. It would be interesting to ascertain 
why some patients persisted with chemotherapy despite having low risk scores. 
Finally more information regarding the socio-educational background and 
understanding of recurrence might be helpful in future research. 
Conclusion 
As discussions about the logic and rationale behind different treatment 
recommendations for breast cancer have become increasingly complex, clinicians 
need an increased repertoire of communication skills to explain risks and benefits 
easily, or patients are probably not making informed choices about options. 
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Table 1. Endopredict patient characteristics  
 
 
Age (years) 
Mean (sd) 56.44 (10.90) 
Range  26-77 
Histology 
Ductal  115 
Lobular 28 
Multifocal 6 
Tumour Grade 
I 17 
II 86 
III 43 
More than 1 tumour with 
different grades α 
3  
Nodal Metastases None: 99 
Macro: 29 
Micro alone: 21 
NPI* Mean: 4.04, Mode: 3.24, Min: 2.16, 
Max: 14.40, 
Percentiles: 25:3.32, 50:3.76, 
75:4.39 
Invasive Tumour Size√ Mean: 25.15, Mode: 14.00, Min: 
7.00, Max: 100.80 
Percentiles: 25:14.00, 50: 21.00, 
75:28.00 
 
Evaluable data was available for 149 patients, 2 consenting patients are not included 
in the data analyses because Endopredict test data was not available due to 
technical reasons.  All patients were ER + and Her2 -. 
 
α multifocal tumours, 1 patient had a medullary tumour of grade I and III, 1 patient 
had a mix of lobular tumour grade III and ductal tumour grade II and 1 patient had a 
ductal tumour of grade I and II.  
 
* for 1 patient with multifocal tumour and two NPI scores, the lobular score was used 
 
√ 149 patients – calculations exclude invasive tumour sizes for additional smaller 
tumours for 10 patients  
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Table 2: Initial and final treatment decisions following EndoPredict test results 
 
 
 
Initial decision Test Result Final Decision  
  N=149   N %   N % 
endocrine 88 (59.1%) 
High 42/88 47.7 
Unchanged 14/42 33.3 
Upgraded to 
endocrine and 
chemotherapy 
28/42 66.7 
Low 46/88 52.3 
Unchanged 46/46 100 
Upgraded to 
endocrine and 
chemotherapy 
0/46 0.0 
endocrine and 
chemotherapy 
61 
(40.9%) 
High 32/61 52.5 
Unchanged 29/32 90.6 
Downgraded to 
endocrine alone 3/32 9.4 
Low 29/61 47.5 
Unchanged 5/29 17.2 
Downgraded to 
endocrine alone 24/29 82.8 
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Table 3: Pre and post-test decisional conflict scores and sub-scores 
 N Pre-test 
Mean (SD) 
Post-test 
Mean (SD) 
Mean 
change 
P-value 
Uncertainty 144 27.49 (27.40) 21.76 (23.18) 5.73 0.025 
Uninformed 144 16.15 (13.30) 12.67 (13.76) 3.47 0.009 
Unclear 136 16.12 (14.71) 14.22 (15.59) 1.90 0.222 
Unsupported 136 12.07 (12.58) 10.85 (13.85) 1.23 0.308 
Ineffective 136 17.69 (14.68) 13.01 (15.20) 4.69 0.002 
Total Conflict 136 17.74 (13.59) 14.59 (14.26) 3.15 0.022 
 
Table 4: Comparison of pre- and post-test Decisional Conflict Scale scores by 
treatment decisions 
 
Treatment 
decision 
N Missing Pre-test 
Mean 
(SD) 
Post-test 
Mean (SD) 
Mean 
Change 
P value 
       
Upgrade from 
E to E+C 
26 2 18.46 
(13.99) 
19.53 
(15.50) 
-1.07 0.668 
Downgrade 
from E+C to E 
24 3 19.99 
(16.15) 
18.12 
(18.69) 
1.87 0.726 
Unchanged 86 8 16.90 
(12.77) 
12.11 
(11.85) 
4.78 0.001 
 
 
 
